Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH)
1Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China
2Department of Respiratory Disease, Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou 318000, China
3Department of Respiratory Disease, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
4Changzhi People’s Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China
5Jinhua Municipal Central Hospital, Jinhua 321000, China
6The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China
7West China Hospital of Sichuan University, Chengdu 610041, China
8Tumor Hospital Affiliated to Harbin Medical University, Harbin 150081, China
9The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
10Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan 250014, China
11Sichuan Provincial People’s Hospital, Chengdu 610072, China
12The First Hospital of Jilin University, Changchun 130021, China
13Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China
14The First Affiliated Hospital of Ningbo University, Ningbo 315010, China
15The Second Affiliated Hospital (Binjiang Campus), School of Medicine, Zhejiang University, Hangzhou 310022, China
16Zhuji People’s Hospital, Zhuji 311800, China
17Peking University International Hospital, Beijing 102206, China
18Shengzhou People’s Hospital, Shengzhou 312400, China
19Zhejiang Provincial People’s Hospital, Hangzhou 310014, China
20Chengdu Seventh People’s Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu 610072, China
21Zhejiang Cancer Hospital, Hangzhou 310022, China
22The First Affiliated Hospital of Nanchang University, Nanchang 330006, China
收起